Strides Pharma Subsidiary Gets USFDA Approval for HIV Tablets, Stock Shows Slight Dip

5 Oct 2023 , 11:38 AM

Strides Pharma Science’s stock saw a slight dip despite its subsidiary receiving USFDA approval. Strides Pharma Global Pte. Limited, Singapore, got approval for Efavirenz (600mg), Emtricitabine (200mg), Tenofovir Disproxil Fumarate (300mg) tablets. The stock was trading at around Rs 506.40, down 0.35%, in the morning trade on the BSE.

These tablets are bioequivalent and therapeutically equivalent to Atripla Tablets of Gilead Sciences LLC. This approval adds to Strides’ list of products in the HIV treatment category through the PEPFAR pathway, totaling 15 products. The tablets will be manufactured in Bengaluru and qualify the company for global donor-funded programs, estimated at ~$15 million USD for EET Tablets procurement in 2022.

Strides aims to launch approximately 60 new products in the US over the next three years. The company has a total of 260 cumulative ANDA filings with USFDA, with over 230 ANDAs approved.

For feedback and suggestions, write to us at [e-mail]